Loading…
Myxoid liposarcoma: it's a hippo's world
Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated pr...
Saved in:
| Published in: | EMBO molecular medicine 2019-05, Vol.11 (5), p.1-n/a |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5790-850299dd84a7600d226d9ef10ddf81648201c588678726f4a88e5634734b0b1d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5790-850299dd84a7600d226d9ef10ddf81648201c588678726f4a88e5634734b0b1d3 |
| container_end_page | n/a |
| container_issue | 5 |
| container_start_page | 1 |
| container_title | EMBO molecular medicine |
| container_volume | 11 |
| creator | Regina, Carla Hettmer, Simone |
| description | Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann
et al
in this issue of
EMBO Molecular Medicine
utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated protein 1 (YAP1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS. These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS. Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP1 expression in MLS, to facilitate treatment decisions and advance therapy.
Graphical Abstract
S. Hettmer and C. Regina discuss the study by Trautmann
et al
(in this issue of
EMBO Molecular Medicine
), which identifies YAP1 positive role in myxoid liposarcomas (MLS) viability and growth, thus highlighting a novel target for therapeutic intervention in MLS. |
| doi_str_mv | 10.15252/emmm.201910470 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0d15cfd0238d4d53a606cf439bc86840</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_0d15cfd0238d4d53a606cf439bc86840</doaj_id><sourcerecordid>2268371049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5790-850299dd84a7600d226d9ef10ddf81648201c588678726f4a88e5634734b0b1d3</originalsourceid><addsrcrecordid>eNqFkU1PGzEQhi3UqlDaMzcUqYdyCYy_bQ5IFaItEhEXerYc2xsc7a4XO4Hm39ewNIVKVU8e2c88ej2D0AGGY8wJJyeh67pjAlhjYBJ20B6WXE6ZUOzNtpZiF70vZQkguMDqHdqloKWWGPbQ0WzzM0U_aeOQis0udfZ0Elefy8RObuMwpFo9pNz6D-htY9sSPj6f--jH14ub8-_Tq-tvl-dfrqaOSw1TxYFo7b1iVgoAT4jwOjQYvG8UFkzVrI4rJaSSRDTMKhW4oExSNoc59nQfXY5en-zSDDl2Nm9MstE8XaS8MDavomuDAY-5azwQqjzznFoBwjWM6rlTdQBQXWeja1jPu-Bd6FfZtq-kr1_6eGsW6d4IDpzLR8HRsyCnu3UoK9PF4kLb2j6kdTGEgBaAiaQV_fQXukzr3NdRVUooWqfNdKVORsrlVEoOzTYMBvO0UfO4UbPdaO04fPmHLf97hRU4HYGH2IbN_3zmYjabvbTD2FxqX78I-U_qfwX6BVkzuco</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2268371049</pqid></control><display><type>article</type><title>Myxoid liposarcoma: it's a hippo's world</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Regina, Carla ; Hettmer, Simone</creator><creatorcontrib>Regina, Carla ; Hettmer, Simone</creatorcontrib><description>Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann
et al
in this issue of
EMBO Molecular Medicine
utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated protein 1 (YAP1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS. These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS. Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP1 expression in MLS, to facilitate treatment decisions and advance therapy.
Graphical Abstract
S. Hettmer and C. Regina discuss the study by Trautmann
et al
(in this issue of
EMBO Molecular Medicine
), which identifies YAP1 positive role in myxoid liposarcomas (MLS) viability and growth, thus highlighting a novel target for therapeutic intervention in MLS.</description><identifier>ISSN: 1757-4676</identifier><identifier>EISSN: 1757-4684</identifier><identifier>DOI: 10.15252/emmm.201910470</identifier><identifier>PMID: 30979710</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adapter proteins ; Apoptosis ; Cancer therapies ; Cell cycle ; Chemotherapy ; DNA damage ; EMBO03 ; Gene expression ; Growth factors ; Humans ; Kinases ; Leukemia ; Liposarcoma ; Liposarcoma, Myxoid - enzymology ; Liposarcoma, Myxoid - pathology ; Models, Biological ; Mutation ; News & Views ; Protein-Serine-Threonine Kinases - metabolism ; RNA-mediated interference ; Sarcoma ; Senescence ; Signal Transduction ; Stem cells ; Studies ; Transcription ; Transcription factors ; Tumors ; Views ; Yes-associated protein</subject><ispartof>EMBO molecular medicine, 2019-05, Vol.11 (5), p.1-n/a</ispartof><rights>The Author(s) 2019</rights><rights>2019 The Authors. Published under the terms of the CC BY 4.0 license</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5790-850299dd84a7600d226d9ef10ddf81648201c588678726f4a88e5634734b0b1d3</citedby><cites>FETCH-LOGICAL-c5790-850299dd84a7600d226d9ef10ddf81648201c588678726f4a88e5634734b0b1d3</cites><orcidid>0000-0003-1709-4448</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2268371049/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2268371049?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,11541,25731,27901,27902,36989,36990,44566,46027,46451,53766,53768,75096</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30979710$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Regina, Carla</creatorcontrib><creatorcontrib>Hettmer, Simone</creatorcontrib><title>Myxoid liposarcoma: it's a hippo's world</title><title>EMBO molecular medicine</title><addtitle>EMBO Mol Med</addtitle><addtitle>EMBO Mol Med</addtitle><description>Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann
et al
in this issue of
EMBO Molecular Medicine
utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated protein 1 (YAP1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS. These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS. Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP1 expression in MLS, to facilitate treatment decisions and advance therapy.
Graphical Abstract
S. Hettmer and C. Regina discuss the study by Trautmann
et al
(in this issue of
EMBO Molecular Medicine
), which identifies YAP1 positive role in myxoid liposarcomas (MLS) viability and growth, thus highlighting a novel target for therapeutic intervention in MLS.</description><subject>Adapter proteins</subject><subject>Apoptosis</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemotherapy</subject><subject>DNA damage</subject><subject>EMBO03</subject><subject>Gene expression</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Liposarcoma</subject><subject>Liposarcoma, Myxoid - enzymology</subject><subject>Liposarcoma, Myxoid - pathology</subject><subject>Models, Biological</subject><subject>Mutation</subject><subject>News & Views</subject><subject>Protein-Serine-Threonine Kinases - metabolism</subject><subject>RNA-mediated interference</subject><subject>Sarcoma</subject><subject>Senescence</subject><subject>Signal Transduction</subject><subject>Stem cells</subject><subject>Studies</subject><subject>Transcription</subject><subject>Transcription factors</subject><subject>Tumors</subject><subject>Views</subject><subject>Yes-associated protein</subject><issn>1757-4676</issn><issn>1757-4684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqFkU1PGzEQhi3UqlDaMzcUqYdyCYy_bQ5IFaItEhEXerYc2xsc7a4XO4Hm39ewNIVKVU8e2c88ej2D0AGGY8wJJyeh67pjAlhjYBJ20B6WXE6ZUOzNtpZiF70vZQkguMDqHdqloKWWGPbQ0WzzM0U_aeOQis0udfZ0Elefy8RObuMwpFo9pNz6D-htY9sSPj6f--jH14ub8-_Tq-tvl-dfrqaOSw1TxYFo7b1iVgoAT4jwOjQYvG8UFkzVrI4rJaSSRDTMKhW4oExSNoc59nQfXY5en-zSDDl2Nm9MstE8XaS8MDavomuDAY-5azwQqjzznFoBwjWM6rlTdQBQXWeja1jPu-Bd6FfZtq-kr1_6eGsW6d4IDpzLR8HRsyCnu3UoK9PF4kLb2j6kdTGEgBaAiaQV_fQXukzr3NdRVUooWqfNdKVORsrlVEoOzTYMBvO0UfO4UbPdaO04fPmHLf97hRU4HYGH2IbN_3zmYjabvbTD2FxqX78I-U_qfwX6BVkzuco</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Regina, Carla</creator><creator>Hettmer, Simone</creator><general>Nature Publishing Group UK</general><general>EMBO Press</general><general>John Wiley and Sons Inc</general><general>Springer Nature</general><scope>C6C</scope><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1709-4448</orcidid></search><sort><creationdate>201905</creationdate><title>Myxoid liposarcoma: it's a hippo's world</title><author>Regina, Carla ; Hettmer, Simone</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5790-850299dd84a7600d226d9ef10ddf81648201c588678726f4a88e5634734b0b1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adapter proteins</topic><topic>Apoptosis</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemotherapy</topic><topic>DNA damage</topic><topic>EMBO03</topic><topic>Gene expression</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Liposarcoma</topic><topic>Liposarcoma, Myxoid - enzymology</topic><topic>Liposarcoma, Myxoid - pathology</topic><topic>Models, Biological</topic><topic>Mutation</topic><topic>News & Views</topic><topic>Protein-Serine-Threonine Kinases - metabolism</topic><topic>RNA-mediated interference</topic><topic>Sarcoma</topic><topic>Senescence</topic><topic>Signal Transduction</topic><topic>Stem cells</topic><topic>Studies</topic><topic>Transcription</topic><topic>Transcription factors</topic><topic>Tumors</topic><topic>Views</topic><topic>Yes-associated protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Regina, Carla</creatorcontrib><creatorcontrib>Hettmer, Simone</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>EMBO molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Regina, Carla</au><au>Hettmer, Simone</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myxoid liposarcoma: it's a hippo's world</atitle><jtitle>EMBO molecular medicine</jtitle><stitle>EMBO Mol Med</stitle><addtitle>EMBO Mol Med</addtitle><date>2019-05</date><risdate>2019</risdate><volume>11</volume><issue>5</issue><spage>1</spage><epage>n/a</epage><pages>1-n/a</pages><issn>1757-4676</issn><eissn>1757-4684</eissn><abstract>Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann
et al
in this issue of
EMBO Molecular Medicine
utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated protein 1 (YAP1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS. These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS. Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP1 expression in MLS, to facilitate treatment decisions and advance therapy.
Graphical Abstract
S. Hettmer and C. Regina discuss the study by Trautmann
et al
(in this issue of
EMBO Molecular Medicine
), which identifies YAP1 positive role in myxoid liposarcomas (MLS) viability and growth, thus highlighting a novel target for therapeutic intervention in MLS.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30979710</pmid><doi>10.15252/emmm.201910470</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-1709-4448</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-4676 |
| ispartof | EMBO molecular medicine, 2019-05, Vol.11 (5), p.1-n/a |
| issn | 1757-4676 1757-4684 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_0d15cfd0238d4d53a606cf439bc86840 |
| source | Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central |
| subjects | Adapter proteins Apoptosis Cancer therapies Cell cycle Chemotherapy DNA damage EMBO03 Gene expression Growth factors Humans Kinases Leukemia Liposarcoma Liposarcoma, Myxoid - enzymology Liposarcoma, Myxoid - pathology Models, Biological Mutation News & Views Protein-Serine-Threonine Kinases - metabolism RNA-mediated interference Sarcoma Senescence Signal Transduction Stem cells Studies Transcription Transcription factors Tumors Views Yes-associated protein |
| title | Myxoid liposarcoma: it's a hippo's world |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T07%3A28%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myxoid%20liposarcoma:%20it's%20a%20hippo's%20world&rft.jtitle=EMBO%20molecular%20medicine&rft.au=Regina,%20Carla&rft.date=2019-05&rft.volume=11&rft.issue=5&rft.spage=1&rft.epage=n/a&rft.pages=1-n/a&rft.issn=1757-4676&rft.eissn=1757-4684&rft_id=info:doi/10.15252/emmm.201910470&rft_dat=%3Cproquest_doaj_%3E2268371049%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5790-850299dd84a7600d226d9ef10ddf81648201c588678726f4a88e5634734b0b1d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2268371049&rft_id=info:pmid/30979710&rfr_iscdi=true |